Dexamethasone reduced mortality among patients hospitalized with COVID-19, especially those who were also receiving respiratory support.

While dexamethasone, a commonly used corticosteroid, is a standard treatment for severe COVID-19, the study found that it modestly inhibited the release of arginase-1 from neutrophils. This was ...

The second possibility is that Covid has now settled into a rut, which will see it become progressively milder until it ...

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

Currently, the drug dexamethasone is still the only therapeutic shown to be effective against the novel coronavirus for severe patients, the chief of the World Health Organization said Friday.

Dexamethasone: The Game-Changer The first true success of drug repurposing in treating COVID-19 came with the discovery that ...

Compared with placebo, fostamatinib did not increase the number of oxygen-free days among adults hospitalized with COVID-19 and hypoxemia.

The severe acute respiratory syndrome coronavirus 2 just keeps doing what it does oh-so-well: it just keeps mutating and mutating and mutating, resulting in more and more variants. Leading the ...

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

Al-Monitor is an award-winning media outlet covering the Middle East, valued for its independence, diversity and analysis. It is read widely by US, international and Middle East decision makers at the ...